Journal of diabetes investigation 2017 12 01() doi 10.1111/jdi.12783
The aim of the present study was to conduct a meta-analysis of randomized controlled trials (RCTs) that investigated the effects of pioglitazone on blood leptin levels in patients with type 2 diabetes.
MATERIALS AND METHODS
Literature searches were performed using Medline, the Cochrane Controlled Trials Registry, and ClinicalTrials. gov, and RCTs that investigated the effects of pioglitazone on blood leptin levels in patients with type 2 diabetes were selected. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were calculated.
Ten RCTs met the eligibility criteria and were included in the meta-analysis. Significantly lower blood leptin levels were observed in the pioglitazone group (SMD, -0.58; 95% CI, -1.12% to -0.05%; P = 0.02) than in the placebo group. There was no significant difference in blood leptin levels observed between the pioglitazone and oral antidiabetic drug (OAD) groups (SMD, -0.01; 95% CI, -0.20% to 0.19%; P = 0.93).
There was a significant difference in blood leptin levels between the pioglitazone and placebo groups. However, relatively few RCTs were included in the study, and there was a high level of statistical heterogeneity; we believe that this could have affected the results. This article is protected by copyright. All rights reserved.